Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease Global News Select Feb 4, 2025, 7:25:00 AM Supernus Resubmits New Drug Application for Parkinson's Treatment Device ...

Supernus Pharmaceuticals’ first quarter results were met with a negative market reaction, despite revenue and non-GAAP profit ...

Objectives: This study aimed to identify, measure and evaluate expected costs of innovative palonosetron-based antiemetic therapy versus ondansetron-based treatment, the ultimate aim being to ...

Funding information This study was funded by Helsinn Healthcare, Lugano, Switzerland. Reprint Address Dr Rosanna Tarricone, Centre for Research in Healthcare Management, CERGAS – Bocconi ...

Jack Khattar, President and CEO of Supernus Pharmaceuticals, said the acquisition augments the company’s growth profile by adding a fourth growth product to its portfolio, in addition to Qelbree, ...

Last quarter, Supernus also launched ONAPGO (apomorphine hydrochloride injection), a pump to aid delivery of APOKYN, which was finally approved by the FDA at the fourth time of asking, and which ...

Combined with its three other growth products (Qelbree ®, ONAPGO TM, and GOCOVRI ®), Supernus believes it is poised for significant future growth. Augments Supernus central nervous system (CNS ...

Supernus is buying Sage Therapeutics for $561 million, hoping that it can transform a new postpartum depression drug into a standard of care.

® , ONAPGO TM , and GOCOVRI ® ), Supernus believes it is poised for significant future growth. Augments Supernus central nervous system (CNS) discovery platforms and expertise.

Supernus believes that with Zurzuvae joining its three other key growth products, Qelbree, ONAPGO, and GOCOVRI, the company is poised for significant future growth.